**Name of Journal:** *World Journal of Meta-Analysis*

**Manuscript NO:** 63350

**Manuscript Type:** MINIREVIEWS

**Metabolic and biological changes in children with obesity and diabetes**

Matsumoto S *et al*. Metabolic and biological changes in child obesity

Shirou Matsumoto, Tomomi Nakamura, Fusa Nagamatsu, Jun Kido, Rieko Sakamoto, Kimotoshi Nakamura

**Shirou Matsumoto, Fusa Nagamatsu, Jun Kido, Kimotoshi Nakamura,** Department of Pediatrics, Faculty of Medical Sciences, Kumamoto University, Kumamoto 860-8556, Japan

**Tomomi Nakamura, Rieko Sakamoto,** Department of Perinatal Care Unit, Kumamoto University Hospital, Kumamoto University, Kumamoto 860-8556, Japan

**Author contributions:** Matsumoto S and Nakamura T contributed equally to this work; Matsumoto S, Nakamura T, Nagamatsu F, Kido J, Sakamoto R and Nakamura K designed the research study; Matsumoto S, Nakamura T and Nagamatsu F performed the searching of the literature independently; Matsumoto S and Nagamatsu F wrote the manuscript; All authors have read and approve the final manuscript.

**Supported by** Japan Society for the Promotion of Science, No. JP15K09625 (in part); and The International Council on Amino Acid Science Japan Research Funding, No. ICAASJ001.

**Corresponding author: Shirou Matsumoto, MD, PhD, Associate Professor,** Department of Pediatrics, Faculty of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chu-o-ku, Kumamoto 860-8556, Japan. s-pediat@gpo.kumamoto-u.ac.jp

**Received:** January 27, 2021

**Revised:** March 23, 2021

**Accepted:** April 23, 2021

**Published online:**

**Abstract**

The World Health Organization has stated that obesity in childhood is one of the most serious public health challenges of the 21st century. Overweightness and obesity in early childhood lead to a higher risk of overweightness and obesity in adulthood, thus conferring an increased risk of chronic inflammatory conditions, including type 2 diabetes mellitus, cardiovascular diseases, non-alcoholic fatty liver disease, and some cancers. Therefore, metabolome analysis, targeted at screening and intervening in childhood obesity, is very important. Recent studies have indicated that amino acid and lipid metabolism could influence metabolic pathways in children with obesity. For this review, we searched clinical data addressing metabolomic profiles and insulin resistance (IR) in children with obesity from inception to February 2021 in Medline, Web of Science, and Scopus. According to our search, branched-chain amino acids (BCAAs), aromatic amino acids, and acylcarnitines have reportedly been associated with IR as biomarkers for diabetes in children. BCAAs, tyrosine, and phenylalanine could be predictors of the future development of diabetes in nondiabetic subjects. In addition, it is well known that insulin regulates BCAA metabolism, and BCAA is a biomarker for IR. To interpret the mechanism behind metabolic changes in obesity, it is very important to understand the pathways and combinations related with amino acid, lipid and glucose metabolism. In this review, we summarize studies on metabolic changes to understand metabolomics in children with obesity.

**Key Words:** Children with obesity; Diabetes mellitus; Insulin resistance; Amino acids; Acylcarnitine; Metabolomics

Matsumoto S, Nakamura T, Nagamatsu F, Kido J, Sakamoto R, Nakamura K. Metabolic and biological changes in children with obesity and diabetes. *World J Meta-Anal* 2021; In press

**Core Tip:** Metabolome analysis is an important tool for understanding and predicting future risks of diabetes mellitus. There is some reliable literature on adults; however, that concerning children is limited due to a lack of understanding regarding metabolism in growing children. Here, we explain and discuss the biological/metabolic features in growing children and overgrown children, due to an enhanced understanding of the results of metabolome analysis.

**INTRODUCTION**

The number of overweight children under the age of 5 years in 2016 was estimated to be over 41 million worldwide. Symptomatic pediatric lifestyle-related diseases are present in 5%-15% of children with obesity and increase at onset of adolescence, after the late elementary grade. Although there are many published mechanisms underlying the metabolic profile, those of children with obesity remain only partially understood. Obesity in childhood is a risk factor for hyperlipidemia, hypertension, type 2 diabetes mellitus (T2DM), and cardiovascular disorders in early adulthood. Moreover, severely overweight children develop pediatric lifestyle diseases, such as hyperlipidemia, diabetes, and fatty liver[1,2]. Between 1980 and 2014, the number of adults with diabetes increased from 108 million to 422 million[3], with T2DM accounting for > 90% of these cases[4]. Early detection and intervention of obesity in childhood is important to prevent both pediatric and adult lifestyle diseases[5].

Recently, investigations have been conducted on early screening and diagnosis using metabolomics, which avails much information and indications. About 141 reliable articles related to metabolomics in obesity have been published[6]. Samples were collected from blood (serum and plasma) and urine. Detection methods varied, including liquid chromatography tandem-mass spectrometry, gas chromatography tandem mass spectrometry, time-of-flight mass spectrometry, and nuclear magnetic resonance spectroscopy. Detected metabolites, which are related to T2DM and insulin resistance (IR), included amino acids (upregulated: isoleucine, alanine, proline, glutamate, palmitic acid, 2-aminoadipic acid, and lysine; downregulated: glycine, serine, and citrulline), lipids (palmitic acid), and others (propionyl carnitine, carnitine, and 2-aminoadipic acid). Evidently, all metabolites are related to each other in a complex manner; however, the core factor seems to be amino acids, according to the literature. In this review, we focus on amino acid metabolism in obesity and explain important mechanisms that have been established to date.

**SYSTEMATIC REVIEW OF METABOLOMICS IN PEDIATRIC OBESITY**

We searched clinical data addressing metabolomic profiles and IR in children with obesity from inception to February 2021 in Medline, Web of Science, and Scopus. The search strategy was based on medical subject headings terms. Variant combinations of the following terms were applied during the search: “childhood obesity,” “obese children,” “pediatric obesity,” “IR,” “metabolomics,” “amino acids,” and “lipids”. Inclusion and exclusion criteria have been described in a previous study (39 Using Metabolomic Profiles as Biomarkers for Insulin Resistance in Childhood Obesity: A Systematic Review). QUADOMICS was used to evaluate the methodological quality of the included studies. We performed literature selection according to the PRISMA protocol shown in Figure 1[7]. In this review, we summarize not only systematically reviewed data but also basic studies that help in understanding metabolic changes in children with obesity. We were able to detect 13 reliable clinical studies after systematic selection (Table 1).

**AMINO ACID AND INSULIN PROFILES DURING CHILDHOOD IN HEALTHY CHILDREN**

In healthy children, total amino acid concentration tends to increase up to 18 years of age due to the growth and construction of their own bodies. Plasma amino acid concentrations during childhood are summarized in Table 2[8]. Nine amino acids, namely, alanine, arginine, asparagine, methionine, ornithine, phenylalanine, proline, threonine, and tyrosine, decrease during the first year after birth. After 1 year of age, the concentrations tend to increase throughout childhood and adolescence. Nine other amino acids, namely, cystine, glutamine, glycine, histidine, isoleucine, leucine, lysine, tryptophan, and valine, demonstrate a steady increase throughout infancy, childhood, and adolescence. Five amino acids, namely, aspartic acid, citrulline, glutamic acid, serine, and taurine, show a steady concentration throughout childhood. In children with obesity and without IR, total plasma free amino acids demonstrate lower levels than those in healthy controls.

Insulin exhibits change similar to those of total free amino acids, and puberty strongly influences IR, as described in Table 3[9]. During puberty, insulin increase correlates with prepubertal levels. The lower insulin sensitivity observed in prepubertal girls is likely due to a higher growth hormone secretion in pubertal girls or differences[10,11] in insulin peripheral action in both boys and girls[12]. Particularly in boys during puberty, it has been demonstrated that IR and cardiovascular risk increase[13]. Serum insulin increases in association with age, body mass index (BMI), PS, IGF-1 level, and triglyceride (TG) level[9]. In addition, Hosking *et al*[14] found IR to be associated with lower concentrations of branched-chain amino acids (BCAAs), 2-ketobutyrate, citrate, and 3-hydroxybutyrate and higher concentrations of lactate and alanine. These data portray the biochemical consequences of IR as rapid metabolism, ketogenesis, and pyruvate oxidation during normal child growth and development. Hence, when children undergo metabolic analysis, these factors, which potentially influence metabolism in the body, should be considered thoroughly and matched sufficiently in evaluating the results.

**INSULIN REGULATES GLUCOSE METABOLISM AND MODIFIES AMINO ACID METABOLISM**

Insulin regulates glucose homeostasis mainly in the liver, muscle, and fat. Insulin inhibits gluconeogenesis and glycogenolysis, leading to induced glycogen storage[15]. Insulin promotes the uptake, storage, and use of glucose in muscle and fat. Insulin is responsible for the induction of potassium transport in muscle, differentiation into adipocytes[16], production of androgens by ovaries[17], and retention of sodium by the kidney[18]. Insulin performs all these functions by binding with a specific tyrosine kinase-type of transmembrane receptor. The binding of insulin to receptors leads to signal transduction, including insulin-receptor substrate-1 and PI3K, which activates Akt. Akt phosphorylates the Ser9 site of GSK-3b and inhibits its activity, leading to glycogen synthesis (Figure 2).

In addition, insulin, which acts as an inhibitor of protein degradation, reduces essential amino acid concentrations in the post-absorptive state. Insulin infusion leads to hypoaminoacidemia and does not stimulate protein synthesis in skeletal muscle or splanchnic tissues during the post-absorptive state[19]. Insulin infusion decreases muscle protein degradation and does not enhance protein synthesis without amino acid intake[10,20,21]. In growing children without IR, total plasma free amino acid levels are lower than those of adults (Table 3).

**METABOLIC CHANGE IN PREDIABETES AND T2DM**

Metabolic change in adults is summarized in Figure 3. BCAAs are known to be associated with obesity, a phenomenon first reported by Felig *et al*[22] in 1969. The plasma concentrations of BCAAs and aromatic amino acids (ArAAs), such as Phe and Tyr, were increased and that of glycine was decreased in individuals with obesity when compared to those of age- and sex-matched healthy controls. Consequently, Newgard *et al*[23] reported in 2009that principal component analysis performed on datasets comprised plasma and urine amino acids, acylcarnitines, organic acids, and fatty acids. They identified a cluster of metabolites comprising BCAAs, ArAAs (Phe and Tyr), Glu/Gln, Met, and C3 and C5 acylcarnitines that are strongly associated with IR, suggesting a fundamental alteration of BCAA metabolism in insulin-resistant states. On the other hand, glycine was negatively associated with IR when measured using the homeostatic model assessment (HOMA) score[24] or by hyperinsulinemic-euglycemic clamp[20]. In patients with T2DM, the concentrations of BCAAs can be up to 1.5-fold, or even 2-fold, higher than those in healthy subjects, with a mean change below 1.5-fold (1.2-1.3). These results are reproducible and statistically significant[25-27].

The strong association of BCAAs with IR has been reported in several studies, including a cross-sectional study of subjects with metabolic syndrome and varying BMI[28], a study on Chinese and Asian-Indian subjects residing in Singapore in which BMI was controlled (average BMI of 24)[29], a study on subjects at extremes of insulin sensitivity in the Insulin Resistance Atherosclerosis Study[30], and studies on the effects of combined aerobic and resistance training in insulin-resistant subjects[31]. In all of these studies, the BCAA-related factor was more correlated with IR than any lipid-related factor.

Another candidate metabolite is 2-aminoadipic acid (2-AAA), which is strongly correlated with incident T2DM, with subjects in the top quartile for this metabolite having a > 4-fold increase risk of disease[32]. 2-AAA proved to be an independent biomarker because its levels were not associated with BCAAs or ArAAs in this study.

The association between cardiometabolic diseases and certain lipid metabolites commonly measured in clinical chemistry laboratories - including TGs, cholesterol, and total nonesterified fatty acids - has long been recognized, leading some to conclude that cardiometabolic diseases are driven by perturbed lipid homeostasis. Application of metabolomics has led to a broader appreciation of metabolites that associate with these maladies and, in some cases, metabolites that predict intervention outcomes and future disease development.

**METABOLIC CHANGE IN CHILDREN WITH OBESITY AND IR**

Perng *et al*[33] investigated plasma metabolic profiling in 262 children (6-10 years of age). They found that BCAA-related and androgen-hormone patterns were higher in obese than in lean children. Both patterns were associated with adiposity and worse cardiometabolic profiles. Each increment in the BCAA and androgen pattern scores corresponded with a 6% (95% confidence interval (CI): 1%-13%) higher HOMA-IR. Children of mothers with obesity had higher BCAA scores than in those of mothers without obesity. Perng *et al*[34] also reported a BCAA pattern corresponding with a 4.82 (95%CI: 0.92-8.71) mg/dL decrease in fasting glucose in boys. In girls, the BCAA pattern was associated with an increase in TGs [4.17 (0.03-8.32) mg/dL]. The androgen pattern was associated with decreased leptin [-2.35 (-4.34 to -0.35) ng/dL] and increased C-reactive protein [0.28 (0.03-0.54) mg/dL] in girls. These relationships did not differ by baseline BMI percentile. Sex differences in biomarkers were reported by Newbern *et al*[35]. They investigated metabolome profiles in 82 adolescents with obesity. BCAA levels and byproducts of BCAA catabolism were higher in teenage boys with obesity than in girls of comparable BMI z-scores. A metabolic signature comprising BCAA and uric acid correlates positively with HOMA-IR in males and TG-to-high-density lipoprotein ratio in females and inversely with adiponectin in males but not females.

Perng *et al*[36] also investigated metabolomic profiles of four overweight/obesity and metabolic risk phenotypes among 524 adolescents aged approximately 13 years. Their data demonstrated that long-chain fatty acids, BCAAs, acylcarnitines, diacylglycerols, and steroid hormones differed by weight status and metabolic phenotype. Xia *et al*[37] investigated urinary metabolic analysis in 69 children with overweight/obesity and 80 lean children. They discovered that mono-n-butyl phthalate (MnBP) exposure was significantly associated with overweight/obesity in children and the disrupted arginine and proline metabolism might have played an important role in mediating the putative obesogenesis of MnBP. Moran-Ramos *et al*[38] investigated data from the Obesity Research Study for Mexican Children conducted in Mexico City and included a case control (*n* = 1120), cross-sectional (*n* = 554), and longitudinal study (*n* = 301) of 6-12-year-old children. Principal component analysis presented a serum amino acid profile composed of arginine, leucine/isoleucine, phenylalanine, tyrosine, valine, and proline significantly associated with obesity [odds ratio (OR) = 1.57; 95%CI: 1.45-1.69, *P* = 3.84 × 10-31) and serum TGs (β = 0.067, *P* = 4.5 × 10-21). In the longitudinal cohort, the amino acid profile was associated with serum TG and the risk of hypertriglyceridemia after 2 years (OR = 1.19; 95%CI: 1.03–1.39, *P* = 0.016). They found that an amino acid profile is an independent risk factor for future hypertriglyceridemia in childhood. Goffredo *et al*[39] investigated 180 metabolites in 78 adolescents with obesity with (*n* = 30) or without (*n* = 48) non-alcoholic fatty liver disease (NAFLD) assessed by magnetic resonance imaging. Adolescents with NAFLD had higher plasma levels of valine (*P* = 0.02), isoleucine (*P* = 0.03), tryptophan (*P* = 0.02), and lysine (*P* = 0.02) after adjustment for confounding factors. BCAAs were negatively correlated with peripheral and hepatic insulin sensitivity. Higher baseline valine levels predicted an increase in hepatic fat content at follow-up (*P* = 0.01). Hellmuth *et al*[40] studied 80 children with obesity before and after a 1-year lifestyle intervention program. Only tyrosine was significantly associated with HOMA (*P* < 0.05) at baseline and end, and with change during the intervention (*P* < 0.05). Lee *et al*[41] analyzed 186 plasma metabolites in 109 Korean boys at baseline and after 2 years. Significantly higher levels of BCAAs and several acylcarnitines were observed in children with obesity and as well as lower levels of acyl-alkyl phosphatidylcholines. Baseline BCAAs were significantly positively correlated with both HOMA-IR and continuous metabolic-risk score at the 2-year follow-up. Baseline BCAA concentration was identified as a predictor of future risk of IR and metabolic syndrome. Butte *et al*[42] analyzed the metabolic profiles of 353 Hispanic children without obesity and 450 with obesity. BCAAs, BCAA-catabolites, propionylcarnitine, and butyrylcarnitine were significantly elevated in children with obesity.

Mastrangelo *et al*[43] reported in 2016 on the metabolic profiles of prepubertal children with obesity. They found that BCAAs, ArAAs, alanine, ketoisocaproic acid, pyruvate, and C3 and C4 acylcarnitines increased in children both with obesity and IR (Figure 4). In addition, free carnitine and 3-hydroxyutyrate decreased in children presenting obesity with IR. Because ArAAs potentially compete with BCAAs for transport into mammalian cells, their elevation in serum may indicate a disruption in their transportation into the brain, leading to an excess of BCAAs. Suzuki *et al*[44] reported in 2019 about relationship among amino acids, lipids, and glucose metabolism. In this study, HOMA-IR was positively correlated with BCAAs, ArAAs, Ala, and Glu/Gln, with statistical significance[28]. The mechanism underlying this profiling has not been determined; however, a hypothesis has been suggested. Pozefsky *et al*[45] suggested that impaired insulin activity and decreased utilization of amino acids in the muscles increased plasma BCAA levels owing to reduced uptake of BCAA in the muscles in lifestyle-related diseases. Newgard[46] reasoned that the increased circulating blood BCAA in obese and insulin-resistant subjects partly results from a decline in amino acid (AA) catabolism in their adipose tissue. Readily usable glucose and lipid substrates are considered to obviate the need for AA catabolism in adipose tissue by downregulation of the BCAA catabolic enzymes through the suppression of peroxisome proliferator-activated receptor-γ signaling in such metabolic adaptations. Würtz *et al*[47] reported that gluconeogenesis substrates, including Ala, increased in adults with impaired glucose tolerance. Moreover, Shimizu *et al*[48] reported that depletion of plasma Ala serves as a cue to increase plasma fibroblast growth factor 21 values and enhance liver-fat communication, resulting in the activation of lipolytic genes in adipose tissues. Increases in circulating BCAAs in obesity result in part from decreased rates of their oxidation in adipose tissue, due to coordinated transcriptional suppression of all the BCAA catabolic enzymes as well as from increased phosphorylation and inactivation of the branched-chain ketoacid dehydrogenase (BCKDH) complex in the liver, such that fewer BCAAs are taken up from the blood. Rodent models of obesity exhibit increased hepatic expression of the inhibitory BCKDH kinase, BDK, and reduced expression of the activating BCKDH phosphatase, PPM1K[49]. Transplantation of microbiota from humans with obesity into germ-free mice causes a significant increase in circulating BCAAs and obesity[50]. Hence, gut microbiota is a candidate donor of BCAAs. BCAA biosynthetic pathways are induced in the gut microbiota of obese compared to that of lean humans.

**CONCLUSION**

Obesity leading to several complications during adulthood is a critical issue to be resolved and protected against during childhood. Metabolomics is a common tool for investigating not only adult but also children with obesity, whose data potentially provide clear fundamental mechanisms and evaluations. Nutrient factors, such as glucose, amino acids, and lipids, influence and relate with each other; nevertheless, amino acids are a critical modifier in obesity. Because amino acids reflect the internal metabolic change and intestinal microbiota and act as metabolic modulators, monitoring of amino acids by metabolome analysis may be a useful method to predict metabolic disorders during childhood.

**ACKNOWLEDGEMENTS**

We thank all the staff at our institution who cooperated in the collection of patient samples as well as those at the Department of Central Clinical Laboratory, Kumamoto University Hospital, who performed the laboratory examinations and cervical ultrasonography.

**REFERENCES**

1 **Must A**, Strauss RS. Risks and consequences of childhood and adolescent obesity. *Int J Obes Relat Metab Disord* 1999; **23 Suppl 2**: S2-11 [PMID: 10340798 DOI: 10.1038/sj.ijo.0800852]

2 **Styne DM**. Childhood and adolescent obesity. Prevalence and significance. *Pediatr Clin North Am* 2001; **48**: 823-854, vii [PMID: 11494639 DOI: 10.1016/s0031-3955(05)70344-8]

3 **NCD Risk Factor Collaboration (NCD-RisC)**. Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. *Lancet* 2016; **387**: 1513-1530 [PMID: 27061677 DOI: 10.1016/S0140-6736(16)00618-8]

4 **Howarth FC**, Shafiullah M, Qureshi MA. Chronic effects of type 2 diabetes mellitus on cardiac muscle contraction in the Goto-Kakizaki rat. *Exp Physiol* 2007; **92**: 1029-1036 [PMID: 17675413 DOI: 10.1113/expphysiol.2007.038703]

5 **Groner JA**, Joshi M, Bauer JA. Pediatric precursors of adult cardiovascular disease: noninvasive assessment of early vascular changes in children and adolescents. *Pediatrics* 2006; **118**: 1683-1691 [PMID: 17015562 DOI: 10.1542/peds.2005-2992]

6 **Long J**, Yang Z, Wang L, Han Y, Peng C, Yan C, Yan D. Metabolite biomarkers of type 2 diabetes mellitus and pre-diabetes: a systematic review and meta-analysis. *BMC Endocr Disord* 2020; **20**: 174 [PMID: 33228610 DOI: 10.1186/s12902-020-00653-x]

7 **Liberati A**, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *PLoS Med* 2009; **6**: e1000100 [PMID: 19621070 DOI: 10.1371/journal.pmed.1000100]

8 **Lepage N**, McDonald N, Dallaire L, Lambert M. Age-specific distribution of plasma amino acid concentrations in a healthy pediatric population. *Clin Chem* 1997; **43**: 2397-2402 [PMID: 9439460]

9 **Ballerini MG**, Bergadá I, Rodríguez ME, Keselman A, Bengolea VS, Pipman V, Domené HM, Jasper HG, Ropelato MG. Insulin level and insulin sensitivity indices among healthy children and adolescents. *Arch Argent Pediatr* 2016; **114**: 329-336 [PMID: 27399010 DOI: 10.5546/aap.2016.eng.329]

10 **Arslanian SA**, Heil BV, Becker DJ, Drash AL. Sexual dimorphism in insulin sensitivity in adolescents with insulin-dependent diabetes mellitus. *J Clin Endocrinol Metab* 1991; **72**: 920-926 [PMID: 2005219 DOI: 10.1210/jcem-72-4-920]

11 **Guercio G**, Rivarola MA, Chaler E, Maceiras M, Belgorosky A. Relationship between the growth hormone/insulin-like growth factor-I axis, insulin sensitivity, and adrenal androgens in normal prepubertal and pubertal girls. *J Clin Endocrinol Metab* 2003; **88**: 1389-1393 [PMID: 12629134 DOI: 10.1210/jc.2002-020979]

12 **Hoffman RP**, Vicini P, Sivitz WI, Cobelli C. Pubertal adolescent male-female differences in insulin sensitivity and glucose effectiveness determined by the one compartment minimal model. *Pediatr Res* 2000; **48**: 384-388 [PMID: 10960508 DOI: 10.1203/00006450-200009000-00022]

13 **Moran A**, Jacobs DR Jr, Steinberger J, Steffen LM, Pankow JS, Hong CP, Sinaiko AR. Changes in insulin resistance and cardiovascular risk during adolescence: establishment of differential risk in males and females. *Circulation* 2008; **117**: 2361-2368 [PMID: 18427135 DOI: 10.1161/CIRCULATIONAHA.107.704569]

14 **Hosking J**, Pinkney J, Jeffery A, Cominetti O, Da Silva L, Collino S, Kussmann M, Hager J, Martin FP. Insulin Resistance during normal child growth and development is associated with a distinct blood metabolic phenotype (Earlybird 72). *Pediatr Diabetes* 2019; **20**: 832-841 [PMID: 31254470 DOI: 10.1111/pedi.12884]

15 **Fleig WE**, Nöther-Fleig G, Steudter S, Enderle D, Ditschuneit H. Regulation of insulin binding and glycogenesis by insulin and dexamethasone in cultured rat hepatocytes. *Biochim Biophys Acta* 1985; **847**: 352-361 [PMID: 3933576 DOI: 10.1016/0167-4889(85)90041-2]

16 **Nahum N**, Forti E, Aksanov O, Birk R. Insulin regulates Bbs4 during adipogenesis. *IUBMB Life* 2017; **69**: 489-499 [PMID: 28371235 DOI: 10.1002/iub.1626]

17 **Graham EJ**, Selgrade JF. A model of ovulatory regulation examining the effects of insulin-mediated testosterone production on ovulatory function. *J Theor Biol* 2017; **416**: 149-160 [PMID: 28069449 DOI: 10.1016/j.jtbi.2017.01.007]

18 **Trevisan R**, Fioretto P, Semplicini A, Opocher G, Mantero F, Rocco S, Remuzzi G, Morocutti A, Zanette G, Donadon V. Role of insulin and atrial natriuretic peptide in sodium retention in insulin-treated IDDM patients during isotonic volume expansion. *Diabetes* 1990; **39**: 289-298 [PMID: 2137801 DOI: 10.2337/diab.39.3.289]

19 **Nygren J**, Nair KS. Differential regulation of protein dynamics in splanchnic and skeletal muscle beds by insulin and amino acids in healthy human subjects. *Diabetes* 2003; **52**: 1377-1385 [PMID: 12765947 DOI: 10.2337/diabetes.52.6.1377]

20 **Chow LS**, Albright RC, Bigelow ML, Toffolo G, Cobelli C, Nair KS. Mechanism of insulin's anabolic effect on muscle: measurements of muscle protein synthesis and breakdown using aminoacyl-tRNA and other surrogate measures. *Am J Physiol Endocrinol Metab* 2006; **291**: E729-E736 [PMID: 16705065 DOI: 10.1152/ajpendo.00003.2006]

21 **Barazzoni R**, Short KR, Asmann Y, Coenen-Schimke JM, Robinson MM, Nair KS. Insulin fails to enhance mTOR phosphorylation, mitochondrial protein synthesis, and ATP production in human skeletal muscle without amino acid replacement. *Am J Physiol Endocrinol Metab* 2012; **303**: E1117-E1125 [PMID: 22967500 DOI: 10.1152/ajpendo.00067.2012]

22 **Felig P**, Marliss E, Cahill GF Jr. Plasma amino acid levels and insulin secretion in obesity. *N Engl J Med* 1969; **281**: 811-816 [PMID: 5809519 DOI: 10.1056/NEJM196910092811503]

23 **Newgard CB**, An J, Bain JR, Muehlbauer MJ, Stevens RD, Lien LF, Haqq AM, Shah SH, Arlotto M, Slentz CA, Rochon J, Gallup D, Ilkayeva O, Wenner BR, Yancy WS Jr, Eisenson H, Musante G, Surwit RS, Millington DS, Butler MD, Svetkey LP. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. *Cell Metab* 2009; **9**: 311-326 [PMID: 19356713 DOI: 10.1016/j.cmet.2009.02.002]

24 **Thalacker-Mercer AE**, Ingram KH, Guo F, Ilkayeva O, Newgard CB, Garvey WT. BMI, RQ, diabetes, and sex affect the relationships between amino acids and clamp measures of insulin action in humans. *Diabetes* 2014; **63**: 791-800 [PMID: 24130332 DOI: 10.2337/db13-0396]

25 **Guasch-Ferré M**, Hruby A, Toledo E, Clish CB, Martínez-González MA, Salas-Salvadó J, Hu FB. Metabolomics in Prediabetes and Diabetes: A Systematic Review and Meta-analysis. *Diabetes Care* 2016; **39**: 833-846 [PMID: 27208380 DOI: 10.2337/dc15-2251]

26 **Roberts LD**, Koulman A, Griffin JL. Towards metabolic biomarkers of insulin resistance and type 2 diabetes: progress from the metabolome. *Lancet Diabetes Endocrinol* 2014; **2**: 65-75 [PMID: 24622670 DOI: 10.1016/S2213-8587(13)70143-8]

27 **Savolainen O**, Fagerberg B, Vendelbo Lind M, Sandberg AS, Ross AB, Bergström G. Biomarkers for predicting type 2 diabetes development-Can metabolomics improve on existing biomarkers? *PLoS One* 2017; **12**: e0177738 [PMID: 28692646 DOI: 10.1371/journal.pone.0177738]

28 **Huffman KM**, Shah SH, Stevens RD, Bain JR, Muehlbauer M, Slentz CA, Tanner CJ, Kuchibhatla M, Houmard JA, Newgard CB, Kraus WE. Relationships between circulating metabolic intermediates and insulin action in overweight to obese, inactive men and women. *Diabetes Care* 2009; **32**: 1678-1683 [PMID: 19502541 DOI: 10.2337/dc08-2075]

29 **Tai ES**, Tan ML, Stevens RD, Low YL, Muehlbauer MJ, Goh DL, Ilkayeva OR, Wenner BR, Bain JR, Lee JJ, Lim SC, Khoo CM, Shah SH, Newgard CB. Insulin resistance is associated with a metabolic profile of altered protein metabolism in Chinese and Asian-Indian men. *Diabetologia* 2010; **53**: 757-767 [PMID: 20076942 DOI: 10.1007/s00125-009-1637-8]

30 **Palmer ND**, Stevens RD, Antinozzi PA, Anderson A, Bergman RN, Wagenknecht LE, Newgard CB, Bowden DW. Metabolomic profile associated with insulin resistance and conversion to diabetes in the Insulin Resistance Atherosclerosis Study. *J Clin Endocrinol Metab* 2015; **100**: E463-E468 [PMID: 25423564 DOI: 10.1210/jc.2014-2357]

31 **Glynn EL**, Piner LW, Huffman KM, Slentz CA, Elliot-Penry L, AbouAssi H, White PJ, Bain JR, Muehlbauer MJ, Ilkayeva OR, Stevens RD, Porter Starr KN, Bales CW, Volpi E, Brosnan MJ, Trimmer JK, Rolph TP, Newgard CB, Kraus WE. Impact of combined resistance and aerobic exercise training on branched-chain amino acid turnover, glycine metabolism and insulin sensitivity in overweight humans. *Diabetologia* 2015; **58**: 2324-2335 [PMID: 26254576 DOI: 10.1007/s00125-015-3705-6]

32 **Wang TJ**, Ngo D, Psychogios N, Dejam A, Larson MG, Vasan RS, Ghorbani A, O'Sullivan J, Cheng S, Rhee EP, Sinha S, McCabe E, Fox CS, O'Donnell CJ, Ho JE, Florez JC, Magnusson M, Pierce KA, Souza AL, Yu Y, Carter C, Light PE, Melander O, Clish CB, Gerszten RE. 2-Aminoadipic acid is a biomarker for diabetes risk. *J Clin Invest* 2013; **123**: 4309-4317 [PMID: 24091325 DOI: 10.1172/JCI64801]

33 **Perng W**, Gillman MW, Fleisch AF, Michalek RD, Watkins SM, Isganaitis E, Patti ME, Oken E. Metabolomic profiles and childhood obesity. *Obesity (Silver Spring)* 2014; **22**: 2570-2578 [PMID: 25251340 DOI: 10.1002/oby.20901]

34 **Perng W**, Rifas-Shiman SL, Hivert MF, Chavarro JE, Oken E. Branched Chain Amino Acids, Androgen Hormones, and Metabolic Risk Across Early Adolescence: A Prospective Study in Project Viva. *Obesity (Silver Spring)* 2018; **26**: 916-926 [PMID: 29575812 DOI: 10.1002/oby.22164]

35 **Newbern D**, Gumus Balikcioglu P, Balikcioglu M, Bain J, Muehlbauer M, Stevens R, Ilkayeva O, Dolinsky D, Armstrong S, Irizarry K, Freemark M. Sex differences in biomarkers associated with insulin resistance in obese adolescents: metabolomic profiling and principal components analysis. *J Clin Endocrinol Metab* 2014; **99**: 4730-4739 [PMID: 25202817 DOI: 10.1210/jc.2014-2080]

36 **Perng W**, Rifas-Shiman SL, Sordillo J, Hivert MF, Oken E. Metabolomic Profiles of Overweight/Obesity Phenotypes During Adolescence: A Cross-Sectional Study in Project Viva. *Obesity (Silver Spring)* 2020; **28**: 379-387 [PMID: 31876390 DOI: 10.1002/oby.22694]

37 **Xia B**, Zhu Q, Zhao Y, Ge W, Zhao Y, Song Q, Zhou Y, Shi H, Zhang Y. Phthalate exposure and childhood overweight and obesity: Urinary metabolomic evidence. *Environ Int* 2018; **121**: 159-168 [PMID: 30208345 DOI: 10.1016/j.envint.2018.09.001]

38 **Moran-Ramos S**, Ocampo-Medina E, Gutierrez-Aguilar R, Macías-Kauffer L, Villamil-Ramírez H, López-Contreras BE, León-Mimila P, Vega-Badillo J, Gutierrez-Vidal R, Villarruel-Vazquez R, Serrano-Carbajal E, Del-Río-Navarro BE, Huertas-Vázquez A, Villarreal-Molina T, Ibarra-Gonzalez I, Vela-Amieva M, Aguilar-Salinas CA, Canizales-Quinteros S. An Amino Acid Signature Associated with Obesity Predicts 2-Year Risk of Hypertriglyceridemia in School-Age Children. *Sci Rep* 2017; **7**: 5607 [PMID: 28717206 DOI: 10.1038/s41598-017-05765-4]

39 **Goffredo M**, Santoro N, Tricò D, Giannini C, D'Adamo E, Zhao H, Peng G, Yu X, Lam TT, Pierpont B, Caprio S, Herzog RI. A Branched-Chain Amino Acid-Related Metabolic Signature Characterizes Obese Adolescents with Non-Alcoholic Fatty Liver Disease. *Nutrients* 2017; **9** [PMID: 28640216 DOI: 10.3390/nu9070642]

40 **Hellmuth C**, Kirchberg FF, Lass N, Harder U, Peissner W, Koletzko B, Reinehr T. Tyrosine Is Associated with Insulin Resistance in Longitudinal Metabolomic Profiling of Obese Children. *J Diabetes Res* 2016; **2016**: 2108909 [PMID: 26881241 DOI: 10.1155/2016/2108909]

41 **Lee A**, Jang HB, Ra M, Choi Y, Lee HJ, Park JY, Kang JH, Park KH, Park SI, Song J. Prediction of future risk of insulin resistance and metabolic syndrome based on Korean boy's metabolite profiling. *Obes Res Clin Pract* 2015; **9**: 336-345 [PMID: 25465494 DOI: 10.1016/j.orcp.2014.10.220]

42 **Butte NF**, Liu Y, Zakeri IF, Mohney RP, Mehta N, Voruganti VS, Göring H, Cole SA, Comuzzie AG. Global metabolomic profiling targeting childhood obesity in the Hispanic population. *Am J Clin Nutr* 2015; **102**: 256-267 [PMID: 26085512 DOI: 10.3945/ajcn.115.111872]

43 **Mastrangelo A**, Martos-Moreno GÁ, García A, Barrios V, Rupérez FJ, Chowen JA, Barbas C, Argente J. Insulin resistance in prepubertal obese children correlates with sex-dependent early onset metabolomic alterations. *Int J Obes (Lond)* 2016; **40**: 1494-1502 [PMID: 27163744 DOI: 10.1038/ijo.2016.92]

44 **Suzuki Y**, Kido J, Matsumoto S, Shimizu K, Nakamura K. Associations among amino acid, lipid, and glucose metabolic profiles in childhood obesity. *BMC Pediatr* 2019; **19**: 273 [PMID: 31387549 DOI: 10.1186/s12887-019-1647-8]

45 **Pozefsky T**, Felig P, Tobin JD, Soeldner JS, Cahill GF Jr. Amino acid balance across tissues of the forearm in postabsorptive man. Effects of insulin at two dose levels. *J Clin Invest* 1969; **48**: 2273-2282 [PMID: 5355340 DOI: 10.1172/JCI106193]

46 **Newgard CB**. Interplay between lipids and branched-chain amino acids in development of insulin resistance. *Cell Metab* 2012; **15**: 606-614 [PMID: 22560213 DOI: 10.1016/j.cmet.2012.01.024]

47 **Würtz P**, Tiainen M, Mäkinen VP, Kangas AJ, Soininen P, Saltevo J, Keinänen-Kiukaanniemi S, Mäntyselkä P, Lehtimäki T, Laakso M, Jula A, Kähönen M, Vanhala M, Ala-Korpela M. Circulating metabolite predictors of glycemia in middle-aged men and women. *Diabetes Care* 2012; **35**: 1749-1756 [PMID: 22563043 DOI: 10.2337/dc11-1838]

48 **Shimizu N**, Maruyama T, Yoshikawa N, Matsumiya R, Ma Y, Ito N, Tasaka Y, Kuribara-Souta A, Miyata K, Oike Y, Berger S, Schütz G, Takeda S, Tanaka H. A muscle-liver-fat signalling axis is essential for central control of adaptive adipose remodelling. *Nat Commun* 2015; **6**: 6693 [PMID: 25827749 DOI: 10.1038/ncomms7693]

49 **She P**, Van Horn C, Reid T, Hutson SM, Cooney RN, Lynch CJ. Obesity-related elevations in plasma leucine are associated with alterations in enzymes involved in branched-chain amino acid metabolism. *Am J Physiol Endocrinol Metab* 2007; **293**: E1552-E1563 [PMID: 17925455 DOI: 10.1152/ajpendo.00134.2007]

50 **Ridaura VK**, Faith JJ, Rey FE, Cheng J, Duncan AE, Kau AL, Griffin NW, Lombard V, Henrissat B, Bain JR, Muehlbauer MJ, Ilkayeva O, Semenkovich CF, Funai K, Hayashi DK, Lyle BJ, Martini MC, Ursell LK, Clemente JC, Van Treuren W, Walters WA, Knight R, Newgard CB, Heath AC, Gordon JI. Gut microbiota from twins discordant for obesity modulate metabolism in mice. *Science* 2013; **341**: 1241214 [PMID: 24009397 DOI: 10.1126/science.1241214]

**Footnotes**

**Conflict-of-interest statement:** The authors declare no conflicts of interest associated with this manuscript.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Corresponding Author's Membership in Professional Societies:** Japanese Society for Amino Acid Science; Japanese Society of Inherited Metabolic diseases; and The Japanese Society for Pediatric Endocrinology.

**Peer-review started:** January 27, 2021

**First decision:** February 25, 2021

**Article in press:**

**Specialty type:** Pediatrics

**Country/Territory of origin:** Japan

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C, C, C

Grade D (Fair): D, D

Grade E (Poor): 0

**P-Reviewer:** Balbaa ME, Correa-Burrows P, Gupta MK, Mrzljak A, Saha S, Zhao CF **S-Editor:** Wang JL **L-Editor:** Filipodia **P-Editor:**

**Figure Legends**



**Figure 1 Flow diagram of the literature search and study selection for “metabolic/biological change in children with obesity and diabetes**”**.**



**Figure 2 Insulin signaling pathway.** After insulin binds to the insulin receptor, which is a type of tyrosine kinase, signal transduction mediated by insulin-receptor substrate-1, PI3K, and AKT is activated by phosphorylation. AKT phosphorylates the Ser9 site of GSK-3b, which inhibits glycogen synthetase (GS). Hence, the insulin signaling pathway leads to glycogen synthesis. AMPK and MTOR are major modulators in metabolism. Insulin resistance and branched-chain amino acids are indicated to influence these mediators.



**Figure 3 Insulin signaling pathway.** BCAAs: Branched-chain amino acids; T2DM: Type 2 diabetes mellitus.



**Figure 4 Metabolic change in children with obesity.** BCAAs: Branched-chain amino acids; T2DM: Type 2 diabetes mellitus.

**Table 1 Characteristics of study findings and identified metabolomic profiles in 13** **clinical studies**

|  |  |  |
| --- | --- | --- |
| **No.** | **Ref.** | **Major finding** |
| 1 | Perng *et al*[36], 2020 | BCAA levels and products of BCAA catabolism were higher in males than females with comparable BMI z-score; In multivariate analyses, HOMA-IR in males correlated positively with BMI z-score and a metabolic signature containing BCAA, uric acid, and long-chain acylcarnitines and negatively with byproducts of complete fatty acid oxidation |
| 2 | Hosking *et al*[14], 2019 | In longitudinal analysis, IR was associated with reduced concentrations of BCAA, 2-ketobutyrate, citrate and 3-hydroxybutyrate, and higher concentrations of lactate and alanine |
| 3 | Suzuki *et al*[44], 2019 | HOMA-IR was positively correlated with valine, leucine, isoleucine, phenylalanine, tryptophan, methionine, threonine, lysine, alanine, tyrosine, glutamate, proline, arginine, ornithine, total free amino acids and aspartate; Blood uric acid levels were positively correlated with leucine and glutamate, and negatively correlated with serine, glycine, and asparagine  |
| 4 | Perng *et al*[34], 2018 | BCAA and androgen hormone metabolite patterns are related to changes in metabolic parameters in a sex-specific manner during early adolescence |
| 5 | Xia *et al*[37], 2018 | Disrupted arginine and proline metabolism associated with phthalate exposure might contribute to the development of overweight and obesity in school-age children |
| 6 | Moran-Ramos *et al*[38], 2017 | Principal component analysis showed a serum amino acid signature composed of arginine, leucine/isoleucine, phenylalanine, tyrosine, valine and proline significantly associated with obesity and serum triglycerides  |
| 7 | Goffredo *et al*[39], 2017 | A branched-chain amino acid-related metabolic signature characterizes obese adolescents with non-alcoholic fatty liver disease |
| 8 | Hellmuth *et al*[40], 2016 | Tyrosine alterations in association with insulin resistance precede alteration in BCAA metabolism |
| 9 | Mastrangelo *et al*[43], 2016 | The majority of metabolites differing between groups were lysophospholipids (15) and amino acids (17), indicating inflammation and central carbon metabolism as the most altered processes in impaired insulin signaling |
| 10 | Lee *et al*[41], 2015 | Obese children presented significantly higher levels of BCAAs and several acylcarnitines and lower levels of acyl-alkyl phosphatidylcholines; Baseline BCAAs were significantly positively correlated with both HOMA-IR and continuous metabolic risk score at the 2-year follow-up |
| 11 | Butte *et al*[42], 2015 | BCAAs and their catabolites, propionylcarnitine and butyrylcarnitine, were significantly elevated in obese children; Lower lysolipids and dicarboxylated fatty acids were seen in obese children; Steroid derivatives were markedly higher in obese children, as were markers of inflammation and oxidative stress |
| 12 | Perng W *et al*[33], 2014 | BCAA and androgen metabolites were associated with adiposity and cardiometabolic risk during mid-childhood |
| 13 | Newbern *et al*[35], 2014 | BCAA levels and byproducts of BCAA catabolism are higher in obese teenage boys than girls of comparable BMI z-score; A metabolic signature comprising BCAA and uric acid correlates positively with HOMA-IR in males and TG to HDL ratio in females and inversely with adiponectin in males but not females |

BCAA: Branched-chain amino acid; BMI: Body mass index; HDL: High-density lipoprotein; HOMA: Homeostatic model assessment; IR: Insulin resistance; TG: Triglycerides.

**Table 2 Plasma amino acid values (mol/L) during childhood**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Amino acid** | **6 mo 50th (10th-90th) quantile value**  | **2 yr 50th (10th-90th) quantile value**  | **6 yr 50th (10th-90th) quantile value**  | **16 yr 50th (10th-90th) quantile value**  |
| Alanine | 248 (182-396) | 229 (173-349) | 234 (182-319) | 370 (240-482) |
| Arginine | 72 (43-120) | 70 (46-90) | 76 (50-99) | 96 (68-128) |
| Asparagine | 41 (31-56) | 38 (29-56) | 42 (31-67) | 55 (37-81) |
| Aspartic acid | 7 (4-18) | 6 (3-8) | 4 (3-6) | 4 (2-5) |
| Citrulline | 26 (14-32) | 28 (17-35) | 30 (23-37) | 30 (23-39) |
| Cystine | 38 (21-53) | 41 (27-52) | 44 (33-54) | 48 (36-61) |
| Glutamic acid | 56 (31-113) | 52 (25-81) | 39 (13-65) | 25 (11-46) |
| Glutamine | 583 (474-737) | 580 (473-692) | 604 (493-724) | 680 (551-797) |
| Glycine | 207 (138-276) | 207 (138-276) | 213 (144-282) | 252 (183-322) |
| Histidine | 76 (61-91) | 76 (61-91) | 78 (63-93) | 92 (77-107) |
| Isoleucine | 53 (39-76) | 55 (4-78) | 54 (40-69) | 60 (47-74) |
| Leucine | 115 (77-153) | 111 (79-147) | 110 (86-136) | 128 (101-159) |
| Lysine | 129 (87-171) | 130 (88-172) | 139 (96-181) | 200 (157-242) |
| Methionine | 55 (25-103) | 19 (13-22) | 20 (14-25) | 26 (20-34) |
| Ornithine | 53 (38-78) | 35 (24-60) | 37 (25-50) | 47 (37-62) |
| Phenylalanine | 52 (38-78) | 49 (39-65) | 49 (40-61) | 57 (47-74) |
| Proline | 93 (151-265) | 128 (93-220) | 127 (93-201) | 184 (113-271) |
| Serine | 126 (98-160) | 121 (97-154) | 118 (96-155) | 130 (101-177) |
| Taurine | 59 (39-111) | 55 (39-80) | 53 (41-69) | 53 (41-66) |
| Threonine | 102 (61-162) | 91 (61-115) | 94 (65-125) | 131 (104-188) |
| Tryptophan | 54 (34-73) | 54 (35-73) | 56 (37-76) | 74 (54-87) |
| Tyrosine | 60 (43-108) | 55 (40-77) | 55 (39-65) | 65 (46-87) |
| Valine | 196 (135-260) | 199 (147-255) | 199 (165-234) | 233 (178-275) |

**Table 3 Insulin, glucose/insulin, and homeostasis model assessment of insulin resistance levels during childhood**

|  |  |  |  |
| --- | --- | --- | --- |
| **Group** | **Insulin** | **Glucose/insulin** | **HOMA-IR** |
|
| Prepubertal  |  |  | 　 |
| ≤ 7.5 yr | 2.9 (1.6-10.9) | 29 (12-50) | 0.6 (0.3-1.4) |
| > 7.5 yr | 5 (1.7-9.6) | 20 (10-47) | 1.1 (0.3-2.0) |
| Pubertal |  |  | 　 |
| Girls | 6.7 (1.8-16.9) | 12 (7.9-44) | 1.6 (0.3-2.6) |
| Boys | 7.3 (2.2-12.9) | 16 (8.0-44) | 1.1 (0.3-2.4) |

G/Ins: Glycemia/insulin ratio; HOMA-IR: Homeostasis model assessment of insulin resistance; Insulin level: μIU/mL: G/Ins ratio: G (mg/dL) and Ins (μIU/mL); HOMA-IR: Ins (μIU/mL) × G (mmol/L)/22.5.